

File: Statistica/PRIN/Neuro/database neuro 01 aprile 2016.sav; Poster ectrims 2016.spv

Data 21 aprile 2016

### Endothelin-1 as a candidate cerebrovascular biomarker in Multiple Sclerosis

Author(s): C Criscuolo<sup>1</sup>, R Lanzillo<sup>1</sup>, A Cianflone<sup>1</sup>, R Liuzzi<sup>2</sup>, M Mancini<sup>2</sup>, E Tedeschi<sup>3</sup>, E Postiglione<sup>1</sup>, G Vacca<sup>1</sup>, V Vacchiano<sup>1</sup>, M Moccia<sup>1</sup>, M Vastola<sup>1</sup>, G Puorro<sup>1</sup>, A Marsili<sup>1</sup>, M Incoronato<sup>4</sup>, M Salvatore<sup>3</sup>, V Brescia Morra<sup>1</sup>

*Institution(s): Federico II University, Neurosciences, Reproductive and Odontostomatological Sciences, Napoli, Italy (1); Institute of Biostructure and Bioimaging - National Research Council, Napoli, Italy (2); Federico II University, Advanced Biomedical Sciences, Napoli, Italy (3); IRCSS SDN Foundation, Napoli, Italy (4)*

**Background:** Clinical and experimental evidence suggests that endothelin-1 (ET-1) plays a role in cardiac and vascular disease **and inhibit remyelination**. Patients with multiple sclerosis (MS) show global cerebral hypoperfusion. The widespread decrease in perfusion in normal-appearing white matter and grey matter in MS seems to be secondary to increased blood concentrations of ET-1.

**Objectives:** To evaluate ET-1 in MS patients vs healthy subjects (HS) in the context of a larger study on the association among MS, amyotrophic lateral sclerosis (ALS), and vascular changes at molecular, genetic, anatomic and functional level.

**Methods:** ET-1 levels will be measured in **300 MS patients, 50 ALS patients and 300 HS** recruited over 3 years. Serum ET-1 levels were coded and assayed with a commercially available ELISA kit in blinded fashion by a laboratory assistant (detection range 0.39–25 pg/mL; R&D Systems).

**Results:** ET-1 levels were performed in 312 MS patients (190 females, 122 males), 311 HS (184 females, 127 males) and in 57 ALS (23 females, 34 males). ET-1 mean were significantly higher in MS compared to HS (**1.74 vs 1.49 pg/mL,  $p < 0.0001$** ) and in ALS compared to HS (2.06 vs 1.49 pg/mL,  $p < 0.0001$ ) at student t-test. ET-1 levels were significantly lower in MS vs ALS (1.74 vs 2.06 pg/mL,  $p = 0.001$ ).

**When stratified for gender, mean ET-1 levels were significantly higher in females MS vs HS (1.71 vs 1.44 pg/mL,  $p = 0.0001$ ).** In MS women ET-1 levels positively correlated with age and disease duration (DD; Pearson correlation coefficient= 0.193,  $p = 0.014$ ; Pearson correlation coefficient= 0.181,  $p = 0.024$ ). No significant relationship was found between age and ET-1 in HS woman ( $p < 0.504$ ). The mean values for age and DD in MS women vs men were nonsignificant.

**Conclusions:** We confirm that serum ET-1 levels are significantly increased in MS patients, **especially in women**. Furthermore, ET-1 levels positively correlate with DD, but not with EDSS and MSSS in women. These findings suggest a role for ET-1 in MS as an index of disease and not of progression, possibly associated to the inflammatory status. In men a protective factor could act, directly or indirectly, reducing ET-1 levels.

**Study Support:** Research and University Ministry

**Key words:** multiple sclerosis, endothelial factors, ET-1